Christina N. Sun

Christina N. Sun

Auto-generated profile, based on publicly available information

Christina N. Sun

UPMC Western Psychiatric Hospital, Pittsburgh, Pennsylvania, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2025 in Journal of Child and Adolescent Psychopharmacology
Verified
Journal Article
Closed access
CSChristina Sun
Christina Sun
ATAndreea Temelie
Andreea Temelie
HGHannah Goulding
Hannah Goulding
CCChristine Clark
Christine Clark
MYMelanie Yabs
Melanie Yabs
TFTanya Fabian
Tanya Fabian
Objectives: There are currently no long-acting injectable antipsychotics (LAIAs) that are approved by the Food and Drug Administration for use in child and adolescent patients, however these agents are used off-label for the treatment of various psychiatric disorders. This study aims to describe the initiation and maintenance dosing strategies of LAIAs in child and adolescent psychiatry inpatients. Methods: This was a single-site retrospective chart review of patients less than 18 years of age initiated on an LAIA during an acute psychiatric hospitalization between October 1, 2015, and October 31, 2022. Patient demographics and hospital encounter information were collected and analyzed using descriptive statistics. Results: Of the 6402 unique pediatric patients discharged from the acute psychiatric hospital within the specified timeframe, 45 (0.7%) were newly initiated on an LAIA. The average age was 15.6 years (range 10–17), with a greater proportion of male ( n = 26, 57.8%) and Black or African American ( n = 27, 60%) patients. The LAIA agents prescribed included paliperidone palmitate ( n = 21, 46.7%), aripiprazole monohydrate ( n = 15, 33.3%), aripiprazole lauroxil ( n = 7, 15.6%), haloperidol decanoate ( n = 1, 2.2%), and risperidone microspheres ( n = 1, 2.2%). Primary diagnosis via International Classification of Diseases-10 code at discharge included schizophrenia spectrum and other psychotic disorders ( n = 19, 42.2%); bipolar disorder ( n = 14, 31.1%); disruptive, impulse control, and conduct disorders ( n = 6, 13.3%); autistic disorder ( n = 5, 11.1%); and attention-deficit/hyperactivity disorder ( n = 1, 2.2%). Seventeen patients (37.8%) received a loading dose regimen and/or a maintenance dose regimen that differed from adult package-insert dosing. The mean length of stay was 23.7 days, and 14 patients (31.1%) were readmitted to the psychiatric hospital within 6 months of discharge. The mean number of days to readmission was 71.9 days. Conclusions: This retrospective study is the first to focus on LAIA initiation and maintenance dosing strategies of multiple agents in both a child and adolescent patient population. Further research is required to evaluate the impact of LAIAs on clinical outcomes in this patient population.

3 April 2025 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
RSRoisin M. Sabol
Roisin M. Sabol
CSChristina N. Sun
Christina N. Sun
CGCasey A. Gudenburr
Casey A. Gudenburr
HZHongyi Zou
Hongyi Zou
TFTanya J. Fabian
Tanya J. Fabian
YXYing Xue
Ying Xue

6 March 2025 in Journal of Child and Adolescent Psychopharmacology
Verified
Journal Article
Closed access
CSChristina Sun
Christina Sun
ATAndreea Temelie
Andreea Temelie
HGHannah Goulding
Hannah Goulding
CCChristine Clark
Christine Clark
MYMelanie Yabs
Melanie Yabs
TFTanya Fabian
Tanya Fabian
Objectives: Current literature shows a benefit in clinical outcomes when long-acting injectable antipsychotics (LAIAs) are utilized in adult patients with psychiatric disorders such as schizophrenia, schizoaffective disorder, and bipolar disorder. Literature regarding LAIA use in pediatric patients is sparse. The objective of this study is to compare the number of acute psychiatric admissions, psychiatric emergency services (PES) visits, and total number of days admitted to an acute psychiatric hospital 1 year prior to and 1-year post-mirror point of index hospitalization and LAIA initiation. Methods: This was a single-site retrospective mirror-image review of patients <18 years of age initiated on an LAIA during an acute psychiatric hospitalization between October 1, 2015, and October 31, 2022. The number of admissions to the acute psychiatric hospital, number of PES visits, and total number of days hospitalized at the acute psychiatric hospital were captured 1-year pre-index hospitalization admission and 1-year post-index hospitalization discharge, with LAIA administration during index hospitalization being the mirror point. Descriptive statistics and a two-tailed paired t -test were utilized to analyze the data. Results: There were 45 unique pediatric patients initiated on an LAIA during the specified timeframe. Across these 45 patients, there were 47 psychiatric admissions 1-year pre-index hospitalization and 38 psychiatric admissions 1-year post-index hospitalization discharge ( p = 0.37). Additionally, there were 24 PES visits 1-year pre-index hospitalization admission and 16 PES visits 1-year post-index hospitalization discharge ( p = 0.25). Finally, across the 45 patients, there were a total of 1040 days admitted to the acute psychiatric hospital in the 1-year prior to index hospitalization admission compared with 774 days admitted to the acute psychiatric hospital in the 1-year post-index hospitalization discharge ( p = 0.48). Conclusions: In this cohort of pediatric patients initiated on an LAIA, there was a positive trend favoring LAIA therapy over oral antipsychotic therapy with LAIA injection as the mirror point; however, there was no statistically significant difference in the number of psychiatric admissions, number of PES visits, or total number of days admitted to an acute psychiatric hospital. Further studies are required to fully understand the impact of LAIA therapy on clinical outcomes for child and adolescent patients with psychiatric disorders.

10 February 2024 in Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
CSChristina N. Sun
Christina N. Sun
LBLucas A. Berenbrok
Lucas A. Berenbrok
JSJames M. Stevenson
James M. Stevenson
We thank Drs. Frye and Nemeroff for their perspective on the promising role of pharmacogenetics (PGx) in the selection of antidepressant treatment [1]. In their article, Frye and Nemeroff discuss several challenges to the wide-scale application of PGx for the treatment of depression. We agree that there are several challenges to address, particularly regarding electronic health record (EHR) integration, in order for PGx to become a widely utilized resource for antidepressant selection and dosing. EHR functionality is required for PGx implementation to succeed, including readily accessible, discrete results and integrated clinical decision support (CDS). PGx laboratory results are shared in several ways with patients and providers: as paper reports which are subsequently scanned into the EHR and/or manually entered into a patient's chart; as electronic files uploaded into the media section of the EHR; in patient or provider-facing websites independent of the EHR; or as laboratory results directly transmitted via HL7 messaging. Returning results and providing CDS in static formats, such as electronic files, do not allow for the interpretation or prescribing recommendations to change as PGx knowledge evolves. For example, the 2023 Clinical Pharmacogenetics Implementation Consortium (CPIC) serotonin reuptake inhibitor guidelines provide actionable recommendations for sertraline based on CYP2B6 metabolizer status, whereas previous CPIC serotonin reuptake inhibitor guidelines did not [2, 3]. CDS returned in electronic file formats prior to 2023 would not contain CYP2B6/sertraline recommendations, therefore not reflecting current consensus. To ensure accurate and high-quality patient care, CDS must be revised periodically and dynamically changed as evidence and treatment recommendations are updated. Furthermore, because PGx results are useful among many disease states, it is crucial that discrete results and CDS are accessible to all clinicians, not just the ordering clinician. For example, patients with depression frequently have comorbid medical diagnoses, such as pain and cardiovascular disease [4]. Medications used to treat these disease states have important drug-gene interactions with genes assayed for antidepressant selection (for example, CYP2C19/clopidogrel, CYP2D6/ codeine), making it imperative that all providers, regardless of specialty, can view and utilize PGx results [5]. While building EHR functionality to support PGx can be a large time investment, current literature shows promise that PGxguided antidepressant treatment may improve symptom remission [6]. As PGx becomes more widely utilized and continues to evolve, so should best practices for EHR functionality. We believe that the incorporation of discrete results and dynamic CDS into the EHR will provide up-to-date treatment guidance and will allow PGx to be robustly studied and utilized across multiple disease states, including major depressive disorder, positively impacting the holistic care of our patients.